The booster dose of BNT162b2 mRNA vaccine in patients after hematopoietic stem cell transplantation: humoral and clinical response and serological conversion predictors

References

• Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N Engl J Med. 2022;386(15):1397–1408. doi:10.1056/nejmoa2118542.
   PubMed Web of Science ®Google Scholar
• Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509–520. doi:10.1056/nejmoa2116044.
   PubMed Web of Science ®Google Scholar
• Maillard A, Redjoul R, Klemencie M, et al. Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients. Blood. 2022;139(1):134–137. doi:10.1182/blood.2019000962.
   Google Scholar
• Majcherek M, Matkowska-Kocjan A, Szymczak D, et al. Two doses of BNT162b2 mRNA vaccine in patients after hematopoietic stem cell transplantation: humoral response and serological conversion predictors. Cancers (Basel). 2022;14(2):325. doi:10.3390/cancers14020325.
   PubMed Web of Science ®Google Scholar
• Chiarucci M, Paolasini S, Isidori A, et al. Immunological response against SARS-COV-2 after BNT162b2 vaccine administration is impaired in allogeneic but not in autologous stem cell transplant recipients. Front Oncol. 2021;11(September):737300. doi:10.3389/fonc.2021.737300.
   PubMedGoogle Scholar
• Piñana JL, López-Corral L, Martino R, et al. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. Am J Hematol. 2022;97(1):30–42. doi:10.1002/ajh.26385.
   PubMed Web of Science ®Google Scholar
• Shem-Tov N, Yerushalmi R, Danylesko I, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients. Br J Haematol. 2022;196(4):884–891. doi:10.1111/BJH.17918.
   PubMed Web of Science ®Google Scholar
• Nishikubo M, Shimomura Y, Maruoka H, et al. Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in allogeneic hematopoietic stem cell transplant recipients: an observational study. J Infect Chemother. 2023;29(3):274–280. doi:10.1016/J.JIAC.2022.11.010.
   PubMed Web of Science ®Google Scholar
• Huang A, Cicin-Sain C, Pasin C, et al. Antibody response to SARS-CoV-2 vaccination in patients following allogeneic hematopoietic cell transplantation. Transplant Cell Ther. 2022;28(4):214.e1–214.e11. doi:10.1016/J.JTCT.2022.01.019.
   PubMedGoogle Scholar
• Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84. doi:10.1056/NEJMOA2114583/SUPPL_FILE/NEJMOA2114583_DATA-SHARING.PDF.
   PubMed Web of Science ®Google Scholar
• Chevallier P, Jullien M, Peterlin P, et al. Effectiveness of a third dose of BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccine over a 6‐month follow‐up period in allogenic hematopoietic stem cells recipients. Hematol Oncol. 2022;40(5):1097–1099. Published online doi:10.1002/HON.3006.
   PubMed Web of Science ®Google Scholar
• Le Bourgeois A, Coste-Burel M, Guillaume T, et al. Safety and antibody response after 1 and 2 doses of BNT162b2 mRNA vaccine in recipients of allogeneic hematopoietic stem cell transplant. JAMA Netw Open. 2021;4(9):e2126344. doi:10.1001/jamanetworkopen.2021.26344.
   PubMed Web of Science ®Google Scholar
• Bai L, Deng S, Reboulet R, et al. Natural killer T (NKT)-B-cell interactions promote prolonged antibody responses and long-term memory to pneumococcal capsular polysaccharides. Proc Natl Acad Sci U S A. 2013;110(40):16097–16102. doi:10.1073/PNAS.1303218110.
   PubMed Web of Science ®Google Scholar
• Burn OK, Pankhurst TE, Painter GF, et al. Harnessing NKT cells for vaccination. Oxf Open Immunol. 2021;2(1):iqab013. doi:10.1093/oxfimm/iqab013.
   PubMedGoogle Scholar
• E, Glu-Demiralp Io E, Alan S, et al. Peripheral innate and adaptive immune cells during COVID-19: functional neutrophils, pro-inflammatory monocytes, and half-dead lymphocytes. 2021. doi:10.1002/cyto.b.22042.
   Google Scholar
• Zarobkiewicz MK, Morawska I, Michalski A, et al. NKT and NKT-like cells in autoimmune neuroinflammatory diseases-multiple sclerosis, myasthenia gravis and Guillain-Barre syndrome. Int J Mol Sci. 2021;22(17):9520. doi:10.3390/ijms22179520.
   PubMed Web of Science ®Google Scholar
• Wu Z, Zheng Y, Sheng J, et al. CD3 + CD4-CD8- (double-negative) T cells in inflammation, immune disorders and cancer. Front Immunol. 2022;13:816005. doi:10.3389/FIMMU.2022.816005.
   PubMed Web of Science ®Google Scholar
• Yang W, Zhang D, Li Z, et al. Predictors of poor serologic response to COVID-19 vaccine in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2022;172:41–50. doi:10.1016/J.EJCA.2022.05.031.
   PubMed Web of Science ®Google Scholar
• Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23(2):186–193. doi:10.1038/s41590-021-01122-w.
   PubMed Web of Science ®Google Scholar
• Riise J, Meyer S, Blaas I, et al. Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination. Br J Haematol. 2022;197(6):697–708. doi:10.1111/BJH.18149.
   PubMed Web of Science ®Google Scholar
• Zaleska J, Kwasnik P, Paziewska M, et al. Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients. Int J Cancer. 2023;152(4):705–712. doi:10.1002/ijc.34209.
   PubMed Web of Science ®Google Scholar
• Flisiak R, Horban A, Jaroszewicz J, et al. Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of February 23, 2022. Pol Arch Intern Med. 2022;132(3):16230. doi:10.20452/PAMW.16230.
   PubMedGoogle Scholar